Wolverine Trading
MYGN icon

Wolverine Trading’s Myriad Genetics MYGN Stock Holding History

Wolverine Trading’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-9,343
Closed -$272K – 4799
2019
Q2 		$260K Buy
+9,343
New +$264K ﹤0.01% 3423
2016
Q3 		– Sell
-23,087
Closed -$586K – 4920
2016
Q2 		$706K Buy
+23,087
New +$802K ﹤0.01% 1891

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wolverine Trading's MYGN Position: Q3 2019 in Review

Wolverine Trading sold out of Myriad Genetics (MYGN) in Q3 2019, closing a stake of 9,343 shares — an estimated $272K sold.

Wolverine Trading first reported a position in MYGN in Q2 2016 and held it in 2 quarters. The position peaked at $706K in Q2 2016. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2019.

  • Wolverine Trading reported no remaining Myriad Genetics position as of Q3 2019 after selling out during the quarter.
  • Wolverine Trading sold 9,343 Myriad Genetics shares in Q3 2019, an estimated $272K.
  • Wolverine Trading first reported a position in Myriad Genetics in Q2 2016 and held it in 2 quarters.
  • Wolverine Trading's Myriad Genetics position peaked at $706K in Q2 2016.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2019.

Based on Wolverine Trading's 13F filing for Q3 2019, filed 14 Nov 2019.